The overarching hypothesis of our translational program is that judicious manipulation of the tumor microenvironment can improve treatment outcome. This application builds upon discoveries made by the Program investigators during the current funding period (2006-2011), that the local and distal stroma collaborate with cancer cells to thwart the effectiveness of anti-VEGF treatments (current Projects 1 and 2) and/or to reduce the delivery and effectiveness of conventional therapeutics (current Project 3). The new Projects 1, 2 and 3 leverage our observation that both common (SDF1a/CXCR4) and specific (ANG2, IL-6, MEK) pathways are activated during anti-VEGF treatments of human glioblastoma, colorectal and hepatocellular carcinomas and this activation correlates with tumor progression during anti-VEGF treatment. Remarkably, the source of these molecules and their target cells are different in each disease, underscoring the need for careful, systematic and separate, yet complementary, molecular and cellular dissection of these pathways for improving outcome in each tumor type. Project 4 leverages the finding that paracrine interactions between tumor-associated fibroblasts and cancer cells contribute to desmoplasia and reduce the blood supply in pancreatic tumors via angiotensin 11 and its downstream effectors, including SDF1a/CXCR4. To this end, all four Projects will test the causal role of the proposed pathways by genetic and pharmacologic inhibition. The pathophysiological consequences on the tumors will be examined using cutting-edge imaging technologies, also developed during the current grant period. Each Project will be supported by (i) a common Bioengineering & Biostatistics Core (Core A), which will continue to provide statistical support and state-of the- art imaging enabling molecular, cellular, anatomical and functional dissection of tumors in their natural microenvironment; (ii) a shared Molecular, Cellular and Morphological Core (Core B) to complement the imaging approaches; (iii) a common Surgery and Animal Core (Core C) known for developing innovative pre clinical models that faithfully capture the clinical situation; and (iv) an Administrative Core (Core D) to provide administrative support and facilitate exchange and dissemination of scientific information.
The proposed translational studies are extremely important and timely as they will advance our basic understanding of the tumor microenvironment as well as inform trial design and help interpret the data from our planned clinical trials with (i) plerixfor - an FDA-approved anti-CXCR4 agent - for glioblastoma, colorectal and liver cancer, (ii) with anti-ANG2 antibody for glioblastoma, and (iii) with FDA-approved angiotensin II receptor blockers for pancreatic cancer.
|Grassberger, Clemens; Hong, Theodore S; Hato, Tai et al. (2018) Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 101:1222-1225|
|Zhang, Na; Chen, Jie; Ferraro, Gino B et al. (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333|
|Aoki, Shuichi; Cobbold, Mark; Zhu, Andrew X et al. (2018) Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology 67:826-828|
|Li, Wende; Liu, Yujiao; Yang, Weining et al. (2018) MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. J Neurooncol 136:63-71|
|Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7|
|Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer 4:292-319|
|Incio, Joao; Ligibel, Jennifer A; McManus, Daniel T et al. (2018) Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med 10:|
|Sung, Yun-Chieh; Liu, Ya-Chi; Chao, Po-Han et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics 8:894-905|
|Jain, Rakesh K; Batista, Ana (2018) A Physical View of Cancer. Trends Cancer 4:257|
|Li, Suyan; Kumar T, Peeyush; Joshee, Sampada et al. (2018) Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior. Cell Res 28:221-248|
Showing the most recent 10 out of 320 publications